脉络膜上腔给药抑制湿性年龄相关性黄斑变性及其他脉络膜新生血管疾病的血管内皮生长因子
本系统综述检索PubMed和Google Scholar截至2024年12月31日的文献,纳入随机对照试验、队列研究和病例对照研究,评估脉络膜上腔递送抗血管内皮生长因子(VEGF)治疗的效果。共识别15篇同行评议文章、3篇新闻稿、6篇会议摘要和报告及8项临床试验。结论指出脉络膜上腔递送可产生比玻璃体内递送更高的脉络膜药物浓度,临床和临床前研究显示有希望的结果,但未来需更多工作充分证明安全性和有效性。
要点
- 脉络膜上腔是巩膜与脉络膜之间的潜在间隙,已成为美国食品药品监督管理局(FDA)批准治疗的递送途径。
- 脉络膜上腔递送抗VEGF治疗可产生比玻璃体内递送更高的脉络膜药物浓度。
- 临床和临床前研究显示脉络膜上腔递送VEGF靶向治疗有希望的结果,但未来需更多工作充分证明安全性和有效性。
核心结论
- 脉络膜上腔递送VEGF靶向治疗在临床和临床前研究中显示出有希望的结果,但未来需要更多工作以更充分地证明安全性和有效性。
研究设计与样本
- 系统综述,检索PubMed和Google Scholar从建库至2024年12月31日的文献,纳入随机对照试验、队列研究和病例对照研究,排除病例报告和综述文章。
主要发现
- 共识别15篇同行评议文章、3篇新闻稿、6篇会议摘要和报告以及8项临床试验与脉络膜上腔递送抗VEGF治疗主题相关。
- 脉络膜上腔递送导致比玻璃体内递送更高的脉络膜药物浓度。
局限性
- 未来需要更多工作以更充分地证明安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Choroidal neovascularization caused by age-related macular degeneration, among other diseases, causes significant visual impairment. Intravitreal therapeutics inhibiting vascular endothelial growth factor (VEGF) signaling have shown excellent safety and efficacy in regressing choroidal neovascularization and improving vision. Current US Food and Drug Administration (FDA)-approved treatments deliver these drugs into the vitreous cavity, even though choroidal neovascularization originates from aberrant signaling in the choroid. DESIGN: Systematic review. METHODS: A literature search was conducted across PubMed and Google Scholar from inception up to December 31, 2024, focusing on studies investigating suprachoroidal delivery of anti-VEGF therapy. Randomized controlled trials, cohort studies, and case-control studies were included, whereas case reports and review articles were excluded. RESULTS: A total of 15 peer-reviewed articles, 3 press releases, 6 conference abstracts and presentations, and 8 clinical trials were identified that were relevant to the topic of suprachoroidal delivery of anti-VEGF therapy. CONCLUSIONS: The suprachoroidal space is a potential space between the sclera and the choroid, which has recently become a route of delivery in an FDA-approved treatment. Notably, suprachoroidal delivery results in higher choroidal drug concentrations than intravitreal delivery. Promising results thus far have been seen with suprachoroidal delivery of VEGF-targeting therapies in clinical and preclinical studies; however, future work is needed to more fully demonstrate safety and efficacy.
引用
- Chiang B, Chung YG, Prausnitz MR, et al. Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization. Am J Ophthalmol. 2025. PMID: 40280278. doi:10.1016/j.ajo.2025.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。